As per Data Bridge Market Research analysis, the enoxaparin market was valued at USD 2.86 billion in 2025 and is projected to reach USD 4.12 billion by 2033, growing at a CAGR of 4.70% from 2026 to 2033.

The market is experiencing consistent growth driven by the rising prevalence of venous thromboembolism (VTE), deep vein thrombosis (DVT), and cardiovascular disorders, along with increasing demand for low-molecular-weight heparins in surgical and post-operative care.

The increasing number of surgical procedures and aging populations globally, combined with growing awareness of thrombosis prevention, is encouraging hospitals and healthcare providers to adopt enoxaparin for the prevention and treatment of blood-clotting disorders. The expanding availability of pre-filled syringes, generic formulations, and biosimilar products, particularly across emerging markets, is further supporting market growth.